Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?

Basit Öğe Kaydı
dc.authoridYILMAZ, Mesut/0000-0003-1466-3887
dc.authoridAcikgoz, Yusuf/0000-0002-0360-7938
dc.authoridErgun, Yakup/0000-0003-4784-6743
dc.authoridUcar, Gokhan/0000-0002-7649-1075
dc.authoridAktürk Esen, Selin/0000-0002-3426-9505;
dc.authorwosidBAL, OZNUR/D-4160-2016
dc.authorwosidYILMAZ, Mesut/AAV-1726-2020
dc.authorwosidAcikgoz, Yusuf/V-1147-2019
dc.authorwosidErgun, Yakup/N-3273-2018
dc.authorwosidUcar, Gokhan/AAA-8198-2021
dc.authorwosidAktürk Esen, Selin/ABX-6180-2022
dc.authorwosidKarakaya, Serdar/ABF-6887-2021
dc.contributor.authorUcar, Gokhan
dc.contributor.authorAcikgoz, Yusuf
dc.contributor.authorErgun, Yakup
dc.contributor.authorBal, Oznur
dc.contributor.authorYilmaz, Mesut
dc.contributor.authorKarakaya, Serdar
dc.contributor.authorAkdeniz, Nadiye
dc.date.accessioned2024-06-12T11:13:31Z
dc.date.available2024-06-12T11:13:31Z
dc.date.issued2020
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIntroduction Treatment options for metastatic renal cell carcinoma disease have been improved in recent years. However, there is still no optimal treatment sequence or combination for metastatic disease. We aimed to investigate whether patients differed in terms of disease outcomes regarding pre-nivolumab tyrosine kinase inhibitors (TKIs). Material and methods The analysis of patients was performed after all cohorts were sub-grouped into two groups according to pre-nivolumab TKIs as following the sunitinib arm and the pazopanib arm. Result A total of 75 patients were included in this study. The median follow-up time was eight months for all cohorts. The objective response rate was statistically significantly higher in the pazopanib arm as compared to the sunitinib arm (56% vs 30%, p=0.02). Progression-free survival was significantly higher in pazopanib than sunitinib (10.3 months vs 5.3 months, p=0.02). Multivariate analysis revealed that pazopanib treatment was associated with better progression-free survival (HR: 0.44, 95 CI; 0.22-0.91, p=0.02). While the median overall survival for patients who had received sunitinib was 11.0 months, it has not been reached the median in the pazopanib arm (11.0 months vs NR, p=0.051). Discussion We demonstrated significantly better progression-free survival and a higher objective response rate with nivolumab treatment in patients who had received pazopanib as compared with patients who received sunitinib in the pre-nivolumab period.en_US
dc.identifier.doi10.7759/cureus.10525
dc.identifier.issn2168-8184
dc.identifier.issue9en_US
dc.identifier.pmid33094066en_US
dc.identifier.urihttps://doi.org/10.7759/cureus.10525
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23584
dc.identifier.volume12en_US
dc.identifier.wosWOS:000570786000006en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringernatureen_US
dc.relation.ispartofCureus Journal Of Medical Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRenal Cell Carcinomaen_US
dc.subjectMetastasisen_US
dc.subjectSunitiniben_US
dc.subjectPazopaniben_US
dc.subjectNivolumaben_US
dc.subjectTrialsen_US
dc.titleSunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu